Effective does not mean optimally dosed
PFMT can help selected conditions without research establishing one best combination of hold time, effort, repetitions, rest and frequency. A programme that helped in a trial is not automatically the only effective programme or the right dose for every reader.
This article concerns the uncertainty in dose comparisons. It does not supply a replacement prescription. Sources were checked on 9 October 2026.
What the dose review could answer
The 2024 Cochrane review included 63 trials with 4920 women and searched through 27 September 2023. Eleven trials compared dose approaches, alongside separate exercise-type and delivery comparisons. Most participants had stress or stress-predominant mixed urinary incontinence; pregnant, recently postpartum and neurological populations were excluded.
Some apparently simple questions still lacked usable outcome data. The abstract reports no data for maximal versus submaximal contractions or upright versus lying positions. The frequency comparison favouring more training days was based on one trial with 68 women and low-certainty quality-of-life evidence. That cannot establish a universal daily target, an optimum rest interval or a rule that more is always better.
For resistance devices, the quality-of-life evidence was very uncertain. Adding equipment should therefore not be presented as a proven way to optimize everyone’s programme. These findings describe measured comparisons, not permission to make an untested dose claim.
Why counting contractions is insufficient
A prescription includes what happens between contractions: whether the muscle releases, whether the next repetition remains controlled, and whether symptoms worsen. Supervision and instruction also differ between studies. If a whole programme improves symptoms, the result does not isolate one hold time as the cause.
Dose comparisons need the same relevant population, comparable support and outcomes that matter to patients. A strength measure alone does not answer how often someone leaks or whether exercise is comfortable. The 2024 review’s primary outcome was incontinence-related quality of life, so its comparisons should be described in those terms.
What current guidance contributes
NICE NG210, recommendations 1.3.15–1.3.16, places supervision with a suitably experienced healthcare professional. Assessment covers contraction and relaxation; the programme is tailored to ability, discomfort and individual goals. Recommendations 1.6.18–1.6.20 include reviewing progress and continuing when the programme is beneficial.
This makes a practical plan possible without claiming to know a universal optimum. An agreed review point allows changes based on technique, symptoms and progress. It does not turn every change into a clinically proven best dose.
How PelvicEx should describe its choices
PelvicEx’s prepared sessions need specific timing to run. Those timings are authored product settings informed by exercise principles and safety boundaries, not trial-proven optima. PelvicEx cannot measure contraction quality, verify relaxation or replace individualized supervision.
Follow a prescribed plan when one exists. Pain, inability to relax, worsening emptying, persistent pressure or a substantial flare requires a pause and appropriate assessment rather than automatic progression. Recent pelvic/prostate surgery, pregnancy and postpartum healing may impose separate restrictions. Seek urgent care for sudden inability to urinate, major bleeding, severe rapidly worsening pain, fever with marked illness, or new saddle/genital numbness with acute bladder, bowel or leg changes.
Related guides
See why there is no universal prescription, changing one training variable at a time and exercise frequency.
Sources
- Hay-Smith EJC et al. Comparisons of approaches to PFMT for urinary incontinence in women. Cochrane, 2024. DOI: 10.1002/14651858.CD009508.pub2. Indexed abstract, dose comparisons.
- NICE. Pelvic floor dysfunction: prevention and non-surgical management, NG210. Supervision and review recommendations.